|
1
|
Goya T, Asamura H, Yoshimura H, Kato H,
Shimokata K, Tsuchiya R, Sohara Y, Miya T and Miyaoka E; Japanese
Joint Committee of Lung Cancer Registry, : Prognosis of 6644
resected non-small cell lung cancers in Japan: A Japanese lung
cancer registry study. Lung Cancer. 50:227–234. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mountain CF: Revisions in the
international system for staging lung cancer. Chest. 111:1710–1717.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sawabata N, Miyaoka E, Asamura H,
Nakanishi Y, Eguchi K, Mori M, Nomori H, Fujii Y, Okumura M and
Yokoi K; Japanese Joint Committee for Lung Cancer Registration, :
Japanese lung cancer registry study of 11,663 surgical cases in
2004: Demographic and prognosis changes over decade. J Thorac
Oncol. 6:1229–1235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: From immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dunn GP, Old LJ and Schreiber RD: The
three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ogino T, Shigyo H, Ishii H, Katayama A,
Miyokawa N, Harabuchi Y and Ferrone S: HLA class I antigen
down-regulation in primary laryngeal squamous cell carcinoma
lesions as a poor prognostic marker. Cancer Res. 66:9281–9289.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ryschich E, Cebotari O, Fabian OV,
Autschbach F, Kleeff J, Friess H, Bierhaus A, Büchler MW and
Schmidt J: Loss of heterozygosity in the HLA class I region in
human pancreatic cancer. Tissue Antigens. 64:696–702. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kooi S, Zhang HZ, Patenia R, Edwards CL,
Platsoucas CD and Freedman RS: HLA class I expression on human
ovarian carcinoma cells correlates with T-cell infiltration in vivo
and T-cell expansion in vivo and T-cell expansion in vitro in low
concentrations of recombinant interleukin-2. Cell Immunol.
174:116–128. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Madjd Z, Spendlove I, Pinder SE, Ellis IO
and Durrant LG: Total loss of MHC class I is an independent
indicator of good prognosis in breast cancer. Int J Cancer.
117:248–255. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Watson NF, Ramage JM, Madjd Z, Spendlove
I, Ellis IO, Scholefield JH and Durrant LG: Immunosurveillance is
active in colorectal cancer as downregulation but not complete loss
of MHC class I expression correlates with a poor prognosis. Int J
Cancer. 118:6–10. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kitamura H, Honma I, Torigoe T, Asanuma H,
Sato N and Tsukamoto T: Down-regulation of HLA class I antigen is
an independent prognostic factor for clear cell renal cell
carcinoma. J Urol. 177:1269–1272. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rolland P, Deen S, Scott I, Durrant L and
Spendlove I: Human leukocyte antigen class I antigen expression is
an independent prognostic factor in ovarian cancer. Clin Cancer
Res. 13:3591–3596. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jager MJ, Hurks HM, Levitskaya J and
Kiessling R: HLA expression in uveal melanoma: There is no rule
without some exception. Hum Immunol. 63:444–451. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Redondo M, Ruiz-Cabello F, Concha A,
Cabrera T, Pérez-Ayala M, Oliva MR and Garrido F: Altered HLA class
I expression in non-small cell lung cancer is independent of c-myc
activation. Cancer Res. 51:2463–2468. 1991.PubMed/NCBI
|
|
15
|
Korkolopoulou P, Kaklamanis L, Pezzella F,
Harris AL and Gatter KC: Loss of antigen-presenting molecules (MHC
class I and TAP-1) in lung cancer. Br J Cancer. 73:148–153. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ramnath N, Tan D, Li Q, Hylander BL,
Bogner P, Ryes L and Ferrone S: Is downregulation of MHC class I
antigen expression in human non-small cell lung cancer associated
with prolonged survival? Cancer Immunol Immunother. 55:891–899.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kikuchi E, Yamazaki K, Torigoe T, Cho Y,
Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H and Nishimura M:
HLA class I antigen expression is associated with a favorable
prognosis in early stage non-small cell lung cancer. Cancer Sci.
98:1424–1430. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Redondo M, Concha A, Ruiz-Cabello F,
Morell M, Esteban F, Talavera P and Garrido F: Class I major
histocompatibility complex antigens and tumor ploidy in breast and
bronchogenic carcinomas. Cancer Detect Prev. 21:22–28.
1997.PubMed/NCBI
|
|
19
|
Hanagiri T, Shigematsu Y, Kuroda K, Baba
T, Shiota H, Ichiki Y, Nagata Y, Yasuda M, Uramoto H, So T, et al:
Prognostic implications of human leukocyte antigen class I
expression in patients who underwent surgical resection for
non-small-cell lung cancer. J Surg Res. 181:e57–e63. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Torigoe T, Asanuma H, Nakazawa E, Tamura
Y, Hirohashi Y, Yamamoto E, Kanaseki T, Hasegawa T and Sato N:
Establishment of a monoclonal anti-pan HLA class I antibody
suitable for immunostaining of formalin-fixed tissue: Unusually
high frequency of down-regulation in breast cancer tissues. Pathol
Int. 62:303–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishikawa K, Miyamoto M, Yoshioka T, Kadoya
M, Li L, Mishra R, Ichinokawa K, Shoji Y, Matsumura Y, Hida Y, et
al: Method for the validation of immunohistochemical staining using
SCID mouse xenografts: Expression of CD40 and CD154 in human
non-small cell lung cancer. Oncol Rep. 29:1315–1321. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ishikawa K, Miyamoto M, Yoshioka T, Kato
T, Kaji M, Ohbuchi T, Hirano S, Itoh T, Dosaka-Akita H and Kondo S:
Up-regulation of CD40 with juxtacrine activity in human nonsmall
lung cancer cells correlates with poor prognosis. Cancer.
113:530–540. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International Union Against Cancer. TNM classification of
malignant tumours. 7th. Wiley-Liss; New York: 2009
|
|
24
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 world health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spranger S, Spaapen RM, Zha Y, Williams J,
Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and
T(regs) in the melanoma tumor microenvironment is driven by CD8(+)
T cells. Sci Transl Med. 5:200ra1162013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shankaran V, Ikeda H, Bruce AT, White JM,
Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes
prevent primary tumour development and shape tumour immunogenicity.
Nature. 410:1107–1111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Raez LE, Fein S and Podack ER: Lung cancer
immunotherapy. Clin Med Res. 3:221–228. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hirschowitz EA, Foody T, Kryscio R,
Dickson L, Sturgill J and Yannelli J: Autologous dendritic cell
vaccines for non-small-cell lung cancer. J Clin Oncol.
22:2808–2815. 2004. View Article : Google Scholar : PubMed/NCBI
|
